Articles from Akanda Corp.

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda (the “Optionee” the “Company”) and 1107385 B.C. LTD (the “Owner”) have agreed upon terms to purchase farming land and related operations and licenses.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that the Company has received a written notification (the “Notification Letter”) on July 3, 2023 from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value ("Common Shares"), was below $1.00 per share for a period of 30 consecutive business days.

International Medical Cannabis Company, Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda and Veridia Canada Ltd. (the “Lender”) have mutually agreed to terminate the loan agreement between the parties previously announced on April 18, 2023 (the “Loan Agreement”). Akanda has returned all funds provided under the terms of the Loan Agreement and has no further obligations owing to the Lender pursuant to the Loan Agreement.

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that it has entered into a loan agreement dated April 26, 2023 (the “Loan Agreement”) with Veridia Canada Ltd. (the “Lender”), in the principal amount of €500,000 (approximately C$738,650) (the “Loan”), which has been advanced in full by the Lender. The Loan is expected to be used for the short-term financial commitments of Akanda and Akanda’s wholly-owned company in Portugal, RPK Biopharma, Unipessoal, LDA (“RPK”), which is indirectly held by Akanda through Holigen Limited (“Holigen”). Holigen is a directly held, wholly-owned subsidiary of the Company.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, today announced that it received a notification letter (the “Notification Letter on Compliance”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the “Nasdaq”) dated March 27, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”).

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, reported that it expects to implement a 1-for-10 reverse stock split on its ordinary shares effective Thursday March 9, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the ordinary shares will continue on the Nasdaq Capital Market under the symbol “AKAN”. The new CUSIP number for the ordinary shares following the reverse stock split is 00971M205.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, reported that it has appointed a new Chief Financial Officer. Effective immediately Shailesh Bhushan will join the company, and comes to Akanda with more than 25 years of financial and accounting experience.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk’s Service Agreement dated June 2, 2021 (the “Service Agreement”) to an immediate end with effect from February 13th, 2023.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that Tejinder Virk resigned from his position as CEO and Director of the Company. Mr. Virk notified the Company of his resignation on February 3, 2023.

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) today announced that it successfully launched its initial supply to German customers recognizing approximately €1,803,996M 1 in sales of EU GMP high-quality indoor-grown medical cannabis in the last quarter of 2022. On a preliminary, unaudited basis, Akanda has recognized its first material revenues since its inception, validating the Company’s strategy to enter the European markets supplying high-end indoor-grown cannabis. These revenues result from only two full months of sales, with the indoor facility shipping only an estimated 40% of the facility's capacity. The Company prepares for the expansion of its indoor cultivation capabilities at its Holigen facility after receiving test results for the highest percentage of THC potency in any cannabis product to be sold within Germany and forecasts sales to double over the next six months.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that Chief Executive Officer Tej Virk has been on a paid leave of absence both administrative and personal since November 30, 2022, pending an independent investigation being conducted by Canmart Directors and counsel. During his leave, Mr. Virk is not expected to perform any responsibilities as the Chief Executive Officer of the Company or any responsibilities as an officer of any of the Company’s subsidiaries.

Medical cannabis cultivation company Akanda Corp. ("Akanda" or the "Company") (NASDAQ: AKAN) (Frankfurt: Y23) is affirming a shift in strategy to become a significant player as a premium EU GMP cultivator in Europe, targeting 10% market share in the German medical cannabis flower market in the near term. Akanda also has a cultivation and dispensary licensing deal with Cookies® in Portugal. These steps put Akanda on firm footing to serve the future regulated adult-use markets in Europe once established.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) expects to take a leading position in the fast-growing German medical cannabis market, as it sees its first export shipment arrive from its Portugal-based operation and announces the first sale has been achieved, solidifying the company as operationally profitable in the market. Akanda recently entered into an agreement to deliver at least 1,000 kilograms of high-grade medical cannabis flower to Germany through the Cansativa platform. The deal ranks as one of the largest supply agreements in the European medical cannabis industry. Cansativa is also the only company in Germany permitted to distribute domestically grown cannabis.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that the Company has received a written notification (the “Notification Letter”) on September 27, 2022 from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value ("Common Shares"), was below $1.00 per share for a period of 30 consecutive business days.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) expects to take a leading position in the fast-growing German medical cannabis market, as it prepares for first export shipment from its Portugal-based Holigen operation in the coming weeks. Akanda’s EU GMP certified indoor grow facility in Sintra received its first purchase order and is expected to make its first export shipment to Germany imminently. Akanda recently entered into an agreement to deliver 1,000 kilograms of high-grade medical cannabis flower to German pharmacies through the Cansativa platform. Cansativa is the only company in Germany permitted to distribute domestically grown cannabis. Cansativa will have a right of first refusal (ROFR) to take on additional quantities that could result in the full capacity utilization of Holigen’s 2,000 kilograms per annum indoor production capacity. The deal ranks as one of the largest supply agreements in the European medical cannabis industry.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced an exclusive license agreement with iconic international cannabis lifestyle brand Cookies. The multi-year agreement enables Akanda to pursue the current medical and future adult-use opportunities in Europe with arguably one of the best-known cannabis brands and highest quality genetics in the world.

International cannabis company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that Terry Booth, the founder of Aurora Cannabis Inc. (“Aurora Cannabis”) (NASDAQ:ACB) has joined Akanda as a Chair of Akanda’s newly formed Advisory Board.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced that Chief Executive Officer Tej Virk will attend the Benzinga Cannabis Capital Conference in Chicago on September 13 and 14. Virk will speak on an expert panel with executives from other international cannabis companies and be available for 1x1 meetings with investors and media throughout the event.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced that it has appointed Tom Flow to the role of Chief Operating Officer of Akanda and Managing Director of Holigen, and Steven George to the role of Commercial Director, effective September 1, 2022. The Company believes that these two hires will enhance its leadership direction and boost profitability across the European medical cannabis market.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced it has signed a multi-year supply agreement with European medical cannabis leader Cansativa GmbH (“Cansativa Group” or “Cansativa”) to supply EU-GMP quality THC dried flower strains cultivated from its Portuguese operations at Holigen. This new supply agreement marks one of the largest for medical cannabis to be exported from Portugal to serve the emerging European medical cannabis market.

Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an international medical cannabis platform company, today announced that the High Court of Lesotho (the “Lesotho Court”) has placed in liquidation the Company’s indirect, wholly-owned subsidiary, Bophelo Bio Science & Wellness (Pty) Ltd. (“Bophelo”). The action to place Bophelo in liquidation was taken by the Lesotho Court pursuant to an unauthorized application and request (the “Liquidation Application”) that was filed by Louisa Mojela, the former Executive Chairman of Akanda, who was recently terminated as Executive Chairman of Akanda, and the Mophuti Matsoso Development Trust (“MMD Trust”), which the Company believes was established by Ms. Mojela.

Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an international medical cannabis platform company, today announced that its UK import and distribution wholly-owned subsidiary CanMart Ltd. (“CanMart”) has partnered with Phlo Connect and Cellen Life Sciences (“Cellen”) to create a first-of-its-kind fully digital dispensing collaboration for medical cannabis. The strategic partnership strengthens CanMart’s existing partnership with Cellen’s digital Leva Clinic and expands its route to market in the UK with a dispensing model that is also fully digital while at the same time improving the experience for UK medical cannabis patients.

Akanda Corp. ("Akanda" or the "Company") today announced certain changes to its board of directors (the "Board") and the postponement of its annual general meeting of shareholders, originally scheduled to take place on June 24, 2022 (the "Meeting").

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced it has closed the acquisition of Holigen Limited (“Holigen”) from The Flowr Corporation (“Flowr”) (TSXV: FLWR, OTC: FLWPF), accelerating Akanda’s seed-to-patient business model in the EMEA region, improving the Company’s ability to meet growing demand for medical cannabis and positioning it for adult use markets as regulations evolve.

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced it has entered into a definitive agreement to acquire 100% of the issued and outstanding shares of Holigen Limited (“Holigen”) from The Flowr Corporation (“Flowr”) (TSXV: FLWR, OTC: FLWPF). The proposed acquisition will significantly accelerate Akanda’s seed-to-patient business model in the EMEA region, improving the Company’s ability to meet growing demand for medical cannabis and positioning it for adult use markets as regulations evolve.

Akanda Corp. ("Akanda" or the “Company”), an international medical cannabis company, today announced the completion of its initial public offering of 4,000,000 common shares at a price of $4.00 per share to the public for a total of $16,000,000 of gross proceeds to the Company (the “Offering”), prior to deducting underwriting discounts, commissions, and other Offering expenses.

Akanda Corp. (NASDAQ: AKAN) (“Akanda” or the “Company”), an international medical cannabis company, today commenced the trading of its common shares on The Nasdaq Capital Market under the ticker symbol “AKAN”. The common shares closed their first day of trading above the offering price at $10.50.

Akanda Corp (NASDAQ: AKAN) (“Akanda” or the “Company”), an international medical cannabis company, today announced the Company’s common shares are scheduled to commence trading this morning Eastern Time on The Nasdaq Capital Market (the “Nasdaq”) under the ticker symbol “AKAN”.

Akanda Corp. ("Akanda" or the “Company”), an international medical cannabis company, today announced the pricing of its initial public offering of 4,000,000 common shares at a price of $4.00 per share to the public for a total of $16,000,000 of gross proceeds to the Company (the “Offering”), prior to deducting underwriting discounts, commissions, and other Offering expenses.

International medical cannabis company Akanda Corp. ("Akanda" or the “Company”) today announced that it has named Dr. Sunny Nayee as its new UK Medical Director. The appointment of Dr. Nayee, a pain treatment expert with direct experience in cannabis therapies, builds upon the company’s partnership with Cellen Life Sciences by combining one of the UK’s top prescribing doctors of medical cannabis with one of the UK’s first fully-digital pain clinics to greatly expand patient access. At Akanda, Dr. Nayee will be responsible for monitoring and improving the overall level of care provided to medical patients in the UK, as well as helping assess expansion into other international markets.

Akanda Corp. ("Akanda" or the “Company”) today announced the appointment of Gila Jones, Gugu Dingaan and Bridget Baker to its Board of Directors as independent directors. Following the appointment of Ms. Jones, Ms. Dingaan and Ms. Baker, the Board will be comprised of seven directors total with four being independent directors.

International medical cannabis company Akanda Corp. ("Akanda" or the “Company”) today announced that it has submitted a confidential draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process and is subject to market and other conditions.

Akanda Corp. ("Akanda" or the “Company”) today announced that it has closed a private placement for aggregate gross proceeds of $5,316,000. The Company intends to use the net proceeds of the private placement for working capital and general corporate purposes.

Akanda Corp. ("Akanda" or the “Company”) today announced that its wholly-owned subsidiary, CanMart Ltd. (“CanMart”), has entered into a distribution agreement with Australia-based Cannim to bring the award-winning Lumir range of medical cannabis products to UK patients. CanMart will import and distribute Cannim’s full-spectrum medical cannabis oil products over a five-year agreement. Cannim satisfies the Australian market with an award-winning Lumir CBD50 which was recently recognised as CBD Product of the Year at the Australian Cannabis Industry Awards.

Akanda Corp. ("Akanda") today announced that Dr. Aslihan Akkar-Schenkl, an experienced executive in the cannabis industry, a registered pharmacist and European Patent Attorney, has joined Akanda as President. Reporting to CEO Tej Virk and Group Executive Chairman Louisa Mojela, Dr. Akkar-Schenkl will be responsible for company-wide Pharmaceutical Strategy & Operations, Quality Assurance, and Legal & Regulatory affairs. She will work closely with Akanda’s EU GMP processing and distribution partner Cantourage GmbH, based in Germany.

Akanda Corp. ("Akanda" or the “Company”) today announced that it has completed the acquisition of Bophelo Bio Science & Wellness (Pty) Ltd. (“Bophelo”) and CanMart Ltd. (“CanMart”) from Halo Collective Inc. ("Halo") (NEO: HALO) (OTCQB: HCANF) (Germany: A9KN). We believe that the acquisition of these two key pieces of the international medical cannabis supply chain positions Akanda to be a leading player in the emerging international medical cannabis industry.